15,822 Penumbra, Inc. $PEN Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC reduced its holdings in Penumbra, Inc. (NYSE:PEN) by 74.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,495 shares of the company’s stock after selling 15,822 shares during the quarter. New York Life Investment Management LLC’s holdings in Penumbra were worth $1,749,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in Penumbra during the second quarter worth $1,356,953,000. HBK Investments L P boosted its position in shares of Penumbra by 12.5% during the 2nd quarter. HBK Investments L P now owns 1,838,508 shares of the company’s stock worth $580,509,000 after purchasing an additional 204,247 shares in the last quarter. Whitebox Advisors LLC purchased a new stake in shares of Penumbra during the 1st quarter worth $146,125,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Penumbra by 130.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 400,160 shares of the company’s stock worth $131,401,000 after purchasing an additional 226,314 shares during the period. Finally, Amundi grew its stake in shares of Penumbra by 302.9% during the 1st quarter. Amundi now owns 345,758 shares of the company’s stock worth $113,537,000 after purchasing an additional 259,936 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PEN has been the subject of several recent analyst reports. Zacks Research upgraded shares of Penumbra from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Weiss Ratings upgraded shares of Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, October 30th. Three research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat.com, Penumbra currently has a consensus rating of “Hold” and a consensus target price of $367.07.

Penumbra Price Performance

Shares of Penumbra stock traded up $0.19 during trading on Friday, hitting $320.96. 237,595 shares of the company were exchanged, compared to its average volume of 396,666. Penumbra, Inc. has a fifty-two week low of $274.55 and a fifty-two week high of $362.41. The company has a quick ratio of 3.92, a current ratio of 5.89 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average price of $320.18 and a 200 day moving average price of $326.09. The stock has a market capitalization of $12.65 billion, a price-to-earnings ratio of 80.85 and a beta of 0.71.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Thursday, October 29th. The company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.13). The firm had revenue of $410.15 million during the quarter, compared to analyst estimates of $401.41 million. Penumbra had a net margin of 10.06% and a return on equity of 10.39%. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 earnings per share. On average, equities analysts expect that Penumbra, Inc. will post 4.96 earnings per share for the current fiscal year.

About Penumbra

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.